Tremelimumab AstraZeneca यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - karcinom, pljučni pljuč - antineoplastična sredstva - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Atacand Plus 32 mg/12,5 mg tablete स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

atacand plus 32 mg/12,5 mg tablete

astrazeneca uk limited - hidroklorotiazid; cileksetilkandesartanat - tableta - hidroklorotiazid 12,5 mg / 1 tableta  cileksetilkandesartanat32 mg / 1 tableta; cileksetilkandesartanat 32 mg / 1 tableta - kandesartan in diuretiki

Atacand Plus 32 mg/25 mg tablete स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

atacand plus 32 mg/25 mg tablete

astrazeneca uk limited - hidroklorotiazid; cileksetilkandesartanat - tableta - hidroklorotiazid 25 mg / 1 tableta  cileksetilkandesartanat32 mg / 1 tableta; cileksetilkandesartanat 32 mg / 1 tableta - kandesartan in diuretiki